Skip to main content
Caplight Logo









Sino-Biocan (Shanghai) Biotech Ltd

Sino-Biocan (Shanghai) Biotech Ltd

Private
ShanghaiHealthcare & Life Scienceshttps://sinobiocan.net/

Last Round

Series B

Mar 27, 2024

Total Funding Raised

$29.7M

Company Overview

Sino-Biocan (Shanghai) Biotech Ltd is a biotechnology company that develops and manufactures automated, modular, closed-system platforms for the production of cellular products used in medicine and biotechnology.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Biotechnology, Medical Devices

Business Model

B2B

Customer Profile

Hardware Sales, Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

cell and gene therapyCGTautomated cell processingclosed-system manufacturingbioprocessing equipmentGMP compliancecell therapy manufacturingbiotech lab automationCDMOcell expansionbioprocess consumablescryopreservationlab automationbiotech hardwareprocess validation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Sino-Biocan (Shanghai) Biotech Ltd Comparables

Compare Sino-Biocan (Shanghai) Biotech Ltd with similar companies based on industry and business-model similarity.

Sino-Biocan (Shanghai) Biotech Ltd comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shenzhen Cellbri Bio-Innovation Technology Co., Ltd.
86%
Ori Biotech
85%
Astraveus
83%

Sino-Biocan (Shanghai) Biotech Ltd Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMar 27, 2024
Series AMar 1, 2022
AngelOct 6, 2021

Sino-Biocan (Shanghai) Biotech Ltd Investors

Notable investors and investment history

Sino-Biocan (Shanghai) Biotech Ltd investors
InvestorRounds
Sinovation VenturesAngel, Series B, Series A
Neovision CapitalSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Mar 27, 2024

    Raised $14M with participation from Neovision Capital and Sinovation Ventures.

  • Mar 1, 2022

    $16M round led by Sinovation Ventures

Sino-Biocan (Shanghai) Biotech Ltd Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Sino-Biocan (Shanghai) Biotech Ltd Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Sino-Biocan (Shanghai) Biotech Ltd's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2013
Last FundingMar 27, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?